These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27224912)

  • 1. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
    Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
    Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
    Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
    Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
    Decombis S; Bellanger C; Le Bris Y; Madiot C; Jardine J; Santos JC; Boulet D; Dousset C; Menard A; Kervoelen C; Douillard E; Moreau P; Minvielle S; Moreau-Aubry A; Tessoulin B; Roue G; Bidère N; Le Gouill S; Pellat-Deceunynck C; Chiron D
    Blood; 2023 Nov; 142(18):1543-1555. PubMed ID: 37562004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.
    Chan W; Schaffer TB; Pomerantz JL
    Mol Cell Biol; 2013 Jan; 33(2):429-43. PubMed ID: 23149938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.
    Jattani RP; Tritapoe JM; Pomerantz JL
    J Biol Chem; 2016 Apr; 291(16):8338-48. PubMed ID: 26884334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Characterization of a Germline Mutation in CARD11 From a Chinese Case of B Cell Expansion With NF-κB and T Cell Anergy.
    Zhao P; Meng Q; Huang Y; Zhang L; Luo S; Zhang X; Tan L; Zhou A; Xiong H; He X
    Front Immunol; 2021; 12():676386. PubMed ID: 34557185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.
    Yang YK; Yang C; Chan W; Wang Z; Deibel KE; Pomerantz JL
    J Biol Chem; 2016 Dec; 291(50):25921-25936. PubMed ID: 27777308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.
    Jattani RP; Tritapoe JM; Pomerantz JL
    J Biol Chem; 2016 Apr; 291(16):8324-36. PubMed ID: 26884335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
    Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
    Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P
    Haematologica; 2017 Nov; 102(11):e447-e451. PubMed ID: 28838994
    [No Abstract]   [Full Text] [Related]  

  • 16. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
    Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
    Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
    Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.